Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IOV-4001 |
| Synonyms | |
| Therapy Description |
IOV-4001 are autologous tumor infiltrating lymphocytes engineered to knockout PD-1 (PDCD1), which potentially increase antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IOV-4001 | IOV 4001|IOV4001 | IOV-4001 are autologous tumor infiltrating lymphocytes engineered to knockout PD-1 (PDCD1), which potentially increase antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05361174 | Phase Ib/II | IOV-4001 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | Recruiting | USA | 0 |